NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company announced the signing of a development contract to manufacture a presentation of ketamine suitable for intravenous administration under current FDA manufacturing regulations.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company announced the signing of a development contract to manufacture a presentation of ketamine suitable for intravenous administration under current FDA manufacturing regulations.